Prospective evaluation of postnatal steroid administration: A 1-year experience from the California Perinatal Quality Care Collaborative

Pediatrics

Volumn 117, Issue 3, 2006, Pages 704-713

  Finer, Neil N ^a   Powers, Richard J ^b   Ou, Chia Hao Simon ^c   Durand, David ^b   Wirtschafter, David ^d   Gould, Jeffrey B ^c  

^a UCSD MEDICAL CENTER   (United States)

^b CHILDREN S HOSPITAL OAKLAND   (United States)

^c STANFORD UNIVERSITY   (United States)

^d KAISER PERMANENTE   (United States)

Author keywords

Chronic lung disease; Hydrocortisone; Hypotension; Preterm infant

Indexed keywords

CORTICOSTEROID DERIVATIVE; DEXAMETHASONE; HYDROCORTISONE; STEROID; GLUCOCORTICOID;

AIRWAY PRESSURE; ARTICLE; BRAIN HEMORRHAGE; BREATHING; CHRONIC LUNG DISEASE; CONTROLLED STUDY; DRUG FATALITY; ENCEPHALOMALACIA; EXTUBATION; HUMAN; HYPOTENSION; INFANT; INTRAVENTICULAR HEMORRHAGE; MAJOR CLINICAL STUDY; PERINATAL CARE; PRIORITY JOURNAL; STRIDOR; TREATMENT INDICATION; UNITED STATES; VERY LOW BIRTH WEIGHT; CHRONIC DISEASE; DRUG SCREENING; INHALATIONAL DRUG ADMINISTRATION; LUNG DISEASE; NEWBORN;

ADMINISTRATION, INHALATION; CHRONIC DISEASE; DEXAMETHASONE; DRUG EVALUATION; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; HYPOTENSION; INFANT, NEWBORN; INFANT, VERY LOW BIRTH WEIGHT; LUNG DISEASES;

EID: 33645037626     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2005-0796     Document Type: Article

References (63)

1. Haddad H, Hsia D, Gellis S. Studies on respiratory rate in the newborn: its use in the evaluation of RDS in IDM. Pediatrics. 1956;17:204-213
2. Altman H. The respiratory distress syndrome of the newborn: a report of 135 cases treated conservatively. S Afr Med J. 1965;39:746-748
3. Baden M, Bauer CR, Colle E, et al. A controlled trial of hydrocortisone therapy in infants with RDS. Pediatrics. 1972;50:526-534
4. Ewerbech H, Helwig H. Treatment of idiopathic respiratory distress with large doses of corticoids. Pediatrics. 1972;49:467-468
5. Bhuta T, Ohlsson A. Systematic review and meta-analysis of early postnatal dexamethasone for prevention of chronic lung disease. Arch Dis Child Fetal Neonatal Ed. 1998;79:F26-F33
6. Halliday HL. Clinical trials of postnatal corticosteroids: inhaled and systemic. Biol Neonate. 1999;76:29-40
7. Halliday HL, Ehrenkranz RA, Doyle LW. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2003;(1):CD001146
8. Halliday HL, Ehrenkranz RA, Doyle LW. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2003;(1):CD001144
9. Halliday HL, Ehrenkranz RA, Doyle LW. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2003;(1):CD001145
10. Finer NN, Craft A, Vaucher YE, et al. Postnatal steroids: short-term gain, long-term pain? J Pediatr. 2000;137:9-13
11. Weichsel ME. The therapeutic use of glucocorticoid hormones in the perinatal period: potential neurological hazards. Ann Neurol. 1977;46:364-366
12. Benesova O, Pavlik A. Perinatal treatment with glucocorticoids and the risk of maldevelopment of the brain. Neuropharmacology. 1989;28:89-97
13. Vicedomini JP, Nonneman AJ, DeKosky ST, et al. Perinatal glucocorticoids disrupt learning: a sexually dimorphic response. Physiol Behav. 1986;36:145-149
14. Huang WL, Beazley LD, Quinlivan JA, et al. Effect of corticosteroids on brain growth in fetal sheep. Obstet Gynecol. 1999;94:213-218
15. Quinlivan JA, Dunlop SA, Newnham JP, et al. Repeated, but not single, maternal administration of corticosteroids delays myelination in the brain of fetal sheep. Prenat Neonatal Med. 1999;4:47-55
16. Uno H, Lohmiller L, Thieme C, et al. Brain damage induced by prenatal exposure to dexamethasone in fetal rhesus macaques. 1. Hippocampus. Dev Brain Res. 1990;53:157-167
17. Blackmon LR, Bell EF, Engle WA, et al. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics. 2002;109:330-338
18. Vermont Oxford Network. 2001 Database Summary. Burlington, VT: Vermont Oxford Network; 2003
19. Stark AR, Carlo W, Bauer C, et al. Complications of early steroid therapy in a randomized controlled trial [abstract]. Pediatrics. 1999;104:739A
20. Soll RF; Vermont Oxford Network Steroid Study Group. Early postnatal dexamethasone therapy for the prevention of chronic lung disease [abstract]. Pediatr Res. 1999;42:123A
21. Papile LA, Tyson JE, Stoll BJ, et al. A multicenter trial of two dexamethasone regimens in ventilator-dependent premature infants. N Engl J Med. 1998;338:1112-1118
22. Stoll BJ, Temprosa M, Tyson JE, et al. Dexamethasone therapy increases infection in very low birth weight infants. Pediatrics. 1999;104(5). Available at: www.pediatrics.org/cgi/content/full/104/5/e63
23. Amin SB, Sinkin RA, McDermott MP, et al. Lipid intolerance in neonates receiving dexamethasone for bronchopulmonary dysplasia. Arch Pediatr Adolesc Med. 1999;153:795-800
24. Van Goudoever JB, Wattimena JD, Carnielli VP, Sulkers EJ, Degenhart HJ, Sauer PJ. Effect of dexamethasone on protein metabolism in infants with bronchopulmonary dysplasia. J Pediatr. 1994;124:112-118.
25. Leitch CA, Ahlrichs J, Karn C, Denne SC. Energy expenditure and energy intake during dexamethasone therapy for chronic lung disease. Pediatr Res. 1999;46:109-113
26. Berry MA, Abrahamowicz M, Usher RH. Factors associated with growth of extremely premature infants during initial hospitalization. Pediatrics. 1997;100:640-646
27. Rizvi ZB, Aniol HS, Myers TF, et al. Effects of dexamethasone on the hypothalamic-pituitary-adrenal axis in preterm infants. J Pediatr. 1992;120:961-965
28. Ng PC, Blackburn ME, Brownlee KG, et al. Adrenal response in very low birthweight babies after dexamethasone treatment for bronchopulmonary dysplasia. Arch Dis Child. 1989;64:1721-1726
29. Kari MA, Heinonen K, Ikonen RS, Koivisto M, Raivio KO. Dexamethasone treatment in preterm infants at risk for bronchopulmonary dysplasia. Arch Dis Child. 1993;68:566-569
30. Shinwell ES, Karplus M, Reich D, et al. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Arch Dis Child Fetal Neonatal Ed. 2000;83:F177-F181
31. Barrington KJ. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. BMC Pediatr. 2001;1:1
32. Doyle LW, Halliday HL, Ehrenkranz RA, et al. Impact of post-natal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease. Pediatrics. 2005;115:655-661
33. Helbock HJ, Insoft RM, Conte FA. Glucocorticoid-responsive hypotension in extremely low birth weight neonates. Pediatrics. 1993;92:715-717
34. Bourchier D, Weston PJ. Randomised trial of dopamine compared with hydrocortisone for the treatment of hypotensive very low birthweight infants. Arch Dis Child Fetal Neonatal Ed. 1997;76:F174-F178
35. Mammel MC, Green TP, Johnson DE, Thompson TR. Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia. Lancet. 1983;1(8338):1356-1358
36. Truffert P, Empana JP, Breart G, et al. Treatment strategies for bronchopulmonary dysplasia with postnatal corticosteroids in Europe: the EURAIL survey. Acta Paediatr. 2003;92:948-951
37. Williams O, Greenough A. Post-natal corticosteroid use. Eur J Pediatr. 2003;162:613-615
38. Wirtschafter DD, Murphy B, Nisbet CC. for the California Perinatal Quality Care Collaborative. Postnatal Steroid Administration Quality Improvement Toolkit. 2003. Available at: www.cpqcc.org/PNS.html. Accessed February 25, 2005
39. Walsh MC, Yao O, Horbar JD, et al. Changes in postnatal steroid (PNS) use in VLBW neonates in 3 large neonatal networks. Pediatr Acad Soc. 2005;57:2078
40. Romagnoli C, Latella C, Zecca E, Papacci P, Tortorolo G. Adrenocortical function and chronic lung disease of pre-maturity: an unresolved problem? J Endocrinol Invest. 2002;25:759-764
41. Watterberg KL, Scott SM, Backstrom C, et al. Links between early adrenal function and respiratory outcome in preterm infants: airway inflammation and patent ductus arteriosus. Pediatrics. 2000;105:320-324
42. Watterberg KL, Gerdes JS, Gifford KL, Lin HM. Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics. 1999;104:1258-1263
43. Watterberg KL, Gerdes JS, Cole C, et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics. 2004;114:1649-1657
44. Demarini S, Dollberg S, Hoath SB, et al. Effects of antenatal corticosteroids on blood pressure in very low birth weight infants during the first 24 hours of life. J Pathol. 1999;19:419-425
45. Smith LM, Ervin MG, Wada N, et al. Antenatal glucocorticoids alter postnatal preterm lamb renal and cardiovascular responses to intravascular volume expansion. Pediatr Res. 2000;47:622-627
46. Ng PC, Lee CH, Lam CW, et al. Transient adrenocortical insufficiency of prematurity and systemic hypotension in very low birthweight infants. Arch Dis Child. 2004;89:119-126
47. Dasgupta SJ, Gill AB. Hypotension in the very low birthweight infant: the old, the new, and the uncertain. Arch Dis Child Fetal Neonatal Ed. 2003;88:F450-F454
48. Hall RW, Kronsberg SS, Barton BA, Kaiser JR, Anand KJ; NEOPAIN Trial Investigators Group. Morphine, hypotension, and adverse outcomes among preterm neonates: who's to blame? Secondary results from the NEOPAIN trial. Pediatrics. 2005;115:1351-1359
49. Osborn D, Evans N, Kluckow M. Randomized trial of dobutamine versus dopamine in preterm infants with low systemic blood flow. J Pediatr. 2002;140:183-191
50. Kluckow M, Evans N. Superior vena cava flow in newborn infants: a novel marker of systemic blood flow. Arch Dis Child Fetal Neonatal Ed. 2000;82:F182-F187
51. Osborn DA, Evans N, Kluckow M. Hemodynamic and antecedent risk factors of early and late periventricular/intraventricular hemorrhage in premature infants. Pediatrics. 2003;112:33-39
52. Evans N, Kluckow M, Simmons M, et al. Which to measure, systemic or organ blood flow? Middle cerebral artery and superior vena cava flow in very preterm infants. Arch Dis Child. 2002;87:181-184
53. Seri I, Tan R, Evans J. Cardiovascular effects of hydrocortisone in preterm infants with pressor-resistant hypotension. Pediatrics. 2001;107:1070-1074
54. Gaissmaier RE, Pohlandt F. Single-dose dexamethasone treatment of hypotension preterm infants. J Pediatr. 1999;134:701-705
55. Zhang J, Penny DJ, Kim NS, Yu VY, Smolich JJ. Mechanisms of blood pressure increase induced by dopamine in hypotensive preterm neonates. Arch Dis Child Fetal Neonatal Ed. 1999;81:F99-F104
56. Bauer K, Linderkamp O, Versmold HT. Systolic blood pressure and blood volume in preterm infants. Arch Dis Child. 1993;69:521-522
57. Aladangady N, Aitchison TC, Beckett C, Holland BM, Kyle BM, Wardrop CA. Is it possible to predict the blood volume of a sick preterm infant? Arch Dis Child Fetal Neonatal Ed. 2004;89:F344-F347
58. Gill AB, Weindling AM. Randomised controlled trial of plasma protein fraction versus dopamine in hypotensive very low birthweight infants. Arch Dis Child. 1993;69:284-287
59. Pladys P, Wodey E, Betremieux P, et al. Effects of volume expansion on cardiac output in the preterm infant. Acta Paediatr. 1997;86:1241-1245
60. Mayock DE, Gleason CA. Cerebrovascular effects of rapid volume expansion in preterm fetal sheep. Pediatr Res. 2004;55:395-399
61. Lindner W, Vossbeck S, Hummler H, et al. Delivery room management of extremely low birthweight infants: spontaneous breathing or intubation? Pediatrics. 1999;103:961-967
62. Verder H, Albertsen P, Ebbesen F, et al. Nasal continuous positive airway pressure and early surfactant therapy for respiratory distress syndrome in newborns of less than 30 weeks' gestation. Pediatrics. 1999;103(2). Available at: www.pediatrics.org/cgi/content/full/103/2/e24
63. Barrington KJ, Bull D, Finer NN. Randomized trial of nasal synchronized intermittent mandatory ventilation compared with continuous positive airway pressure after extubation of very low birth weight infants. Pediatrics. 2001;107:638-641